JPH0156074B2 - - Google Patents
Info
- Publication number
- JPH0156074B2 JPH0156074B2 JP60152326A JP15232685A JPH0156074B2 JP H0156074 B2 JPH0156074 B2 JP H0156074B2 JP 60152326 A JP60152326 A JP 60152326A JP 15232685 A JP15232685 A JP 15232685A JP H0156074 B2 JPH0156074 B2 JP H0156074B2
- Authority
- JP
- Japan
- Prior art keywords
- spf
- substance
- antitumor
- reaction
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000259 anti-tumor effect Effects 0.000 claims description 44
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 241000194017 Streptococcus Species 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000000862 absorption spectrum Methods 0.000 claims description 9
- 229930182555 Penicillin Natural products 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000000921 elemental analysis Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 238000002523 gelfiltration Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 2
- 108700014839 Streptococcus SAGP Proteins 0.000 claims 1
- 239000000243 solution Substances 0.000 description 24
- 239000002609 medium Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 241000193996 Streptococcus pyogenes Species 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 229940056360 penicillin g Drugs 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004748 cultured cell Anatomy 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000194022 Streptococcus sp. Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Natural products S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229910002570 KH2PO4-Na2HPO4 Inorganic materials 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-M cephalosporin C(1-) Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H]([NH3+])C([O-])=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-M 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
Description
【発明の詳細な説明】
本発明は、新規な抗腫瘍性成分SPF―10及びそ
の製法に関するものである。
従来、溶血性連鎖状球菌(以下溶連菌という)
の生菌体を弱毒化して製剤化したものは、すでに
制癌剤として使用されている。
また、溶連菌の菌体を破砕後水または塩類溶液
で有効成分を抽出し、有機溶媒を加えて、抗腫瘍
性成分を沈澱として、回収する方法(特公昭38−
1647)、溶連菌を溶菌酵素リゾチーム、セルラー
ゼまたは蛋白質分解酵素により、溶菌し、活性画
分を水溶性区分として分画する方法(英国特許
1163865号)、溶連菌の菌体を破砕後水不溶性物質
を採取し、核酸分解酵素および蛋白分解酵素で処
理する方法(特開昭55−7014)などが知られてい
る。
このように、ストレプトコツカス属細菌そのも
のもしくはその菌体成分に抗腫瘍活性があること
は広く知られているのであるが、従来知られたも
のは、菌体もしくは水溶性もしくは水不溶性高分
子細胞構成物質であるに過ぎなかつた。菌体もし
くは菌体内から有効成分を単離しようとすれば、
菌体を溶菌したり、機械的に破砕したりして全体
を分画しなければならなかつた。
このような処理では、精製は複雑となり、有効
成分の単離はきわめて困難であつた。実際に分離
し、有効成分として測定された例では分子量
200000の蛋白質(特公昭48−43841、特開昭51−
44617)及び分子量150000の糖蛋白質(特開昭58
−22026)が知られている程度である。
本発明者らは、先に、溶連菌の培養液中に抗腫
瘍性成分を溶出させる方法を求めて研究したとこ
ろ、培養中にペニシリン又はその関連物質を添加
することによつて抗腫瘍性成分が培養液中に溶出
することを見出し(特開昭60−92218号)、培養液
中から生理活性物質SPF―1を分離するに至つた
のである。(特開昭60−30689号)
本発明者らは、更に、溶連菌の培養濾液中から
より有効な成分を分離する目的で鋭意研究したと
ころ、本発明において、癌化白血球培養細胞
L1210(以下培養細胞L1210という)の生育を阻止
し、かつ、アンスロン硫酸法による呈色反応陽性
の画分であることにより特徴づけられる抗腫瘍性
成分SPF―10を分離するに至つた。
本発明の抗腫瘍性成分SPF―10は、元素分析、
呈色反応等から糖を含むペプチド様物質と考えら
れるが、紫外線吸収スペクトルから、既知の抗腫
瘍性物質とは、相異する新規な物質と認められる
ものである。
本発明は、ストレプトコツカス属に属する抗腫
瘍性成分SPF―10生産菌を培養し、培養物から抗
腫瘍性成分SPF―10を採取することを特徴とする
抗腫瘍性成分SPF―10の製造法を包含するもので
ある。
本発明においては、ストレプトコツカス属に属
する抗腫瘍性成分SPF―10生産菌が広く使用でき
る。次に抗腫瘍性成分SPF―10生産菌を記載す
る。
ストレプトコツカス・ピオゲネス
(Streptococcus pyogenes) ATCC 21060
ストレプトコツカス・エスピー
(Streptococcus sp.) ATCC 21597
ストレプトコツカス・ピオゲネス ATCC 21546
ストレプトコツカス・ピオゲネス ATCC 21547
ストレプトコツカス・ピオゲネス ATCC 21548
培養液は、肉エキス培地、酵母エキス培地、ブ
レイン・ハート・インフニージヨン培地(BHI
培地)等の天然培地がよく用いられるが、ストレ
プトコツカス属細菌の生育に適した培地であれば
任意の培地を使用できる。
培養は、PH5.0〜8.0、好ましくは6.1〜7.2であ
り、培養温度は、30〜40℃、好ましくは、35〜37
℃であり、嫌気的に静置培養または、撹拌培養を
行なうことができる。
本発明においては、培養中に適当な時期に、ペ
ニシリンまたは、その関連物質を添加すること
が、抗腫瘍性成分SPF―10の採取に重要な役割を
はたすことになる。
ペニシリンまたは、その関連物質の添加時間は
35〜37℃の培養で、対数増殖期にかかつて後、3
〜20時間の間、特に5〜10時間が好ましい。その
後1〜20時間、好ましくは3〜15時間培養を継続
することにより、培養中に抗腫瘍性成分SPF―10
を多量蓄積させることができる。
ペニシリンまたはその関連物質としては、すで
に知られたペニシリンと類似の作用をもつ関連物
質であればいかなるものでもよいが、ペニシリン
Gが普通用いられる。添加量は、ペニシリンGで
100〜7000単位/ml、好ましくは、300〜5000単
位/ml培養液程度で十分である。
ストレプトコツカス属細菌のペニシリンまた
は、その関連物質の添加培養によつて得られた培
養液は遠心分離によつて菌体を除去し、濾液に硫
安を添加し、50〜90%飽和度の画分を分取する。
得られた抗腫瘍性成分SPF―10を含む硫安塩析物
は、凍結状態で保存することもできる。
この硫安塩析物から抗腫瘍性成分SPF―10を抽
出するには、塩析物を緩衝液に溶解し、この水溶
液をDEAEセルロースカラムに吸着させ、燐酸緩
衝液を用いて段階的に溶出させ、培養細胞L
1210の生育を阻害する活性画分を分取し、この活
性画分をDEAEセフアデツクスA―25カラムに吸
着させ、これを燐酸緩衝液中の塩化ナトリウム濃
度を直線的に上昇させて溶出を行い、その緩衝液
非吸着部分及び塩化ナトリウム低濃度部分を分取
し、これを脱塩し、凍結乾燥することによつて得
ることができる。
次に、実施例1で得られた抗腫瘍性成分SPF―
10の凍結乾燥標品は、次のような理化学的性質を
示す。
1 元素分析
C 45.6〜46.1%
H 6.5〜6.6%
N 14.8〜15.4%
O 29.8〜32.2%
Ash 0.9〜2.1%
2 分解点
本物質は165℃で褐変し、240℃になると黒色と
なり分解する。
3 比旋光度
〔α〕20 D=−65゜.0〜−85.0゜(C=1.00)
4 紫外線吸収スペクトル
本物質0.1%の水溶液の紫外線吸収スペクトル
は第1図に示される。250nmから270nmにかけて
吸収が認められる。
5 赤外線吸収スペクトル
第2図に示される。
3270cm-1付近、2900cm-1、1670cm-1、1535cm
-1、1450cm-1、1400cm-1、1330cm-1、1260cm-1、
1160cm-1、1090cm-1、1030cm-1に吸収が認めら
れる。
6 塩基性、酸性、中性の区別
本物質1.0%の水溶液のPHは6.5である。
7 物質の色
淡黄色
8 呈色反応
ローリー反応 +
ビユーレツト反応 +
ニンヒドリン反応 +
アンスロン硫酸反応 +
モーリツシユ反応 +
システイン硫酸反応 +
オルシン塩酸反応 −
9 分子量
ゲル濾過法による測定では分子量約1000〜
500000である。
10 溶剤に対する溶解性
水に可溶であるが、メタノール、エタノール、
n―プロパノール、アセトン、エチルエーテル、
n―ヘキサン、クロロホルム、酢酸エチル等の溶
剤には、難溶又は不溶である。
次にin vitroにおける培養細胞L 1210に対す
る抗腫瘍性活性の測定方法及びアンスロン硫酸法
による呈色反応の方法を示す。
抗腫瘍活性の測定方法
抗腫瘍活性の測定は、培養細胞L 1210の生育
阻止率(IR%)の測定により行つた。
L 1210細胞を10%FBS添加RPMI 1640培地
(5mg/カナマイシン含有)に懸濁した。この
培養液0.5mlをフアルコン 2058 チユーブに注
加し、細胞数が1×105cells/tubeになるように
した。次いでこの培養液に所定量の標品(抗腫瘍
性成分SPF―10)を目的濃度になるように培養液
に溶解した0.5mlを注加して、37℃で5%CO2存
在下に培養した。標品を添加して48時間後にトリ
パンブルーによる染色をおこない、次式により
IR(%)を算出した。
IR(%)=(A)−各実験群の生細胞数/対照群の生細胞
数×100
ここで(A)とは対照群の生細胞数を示す。
対照は標品を含まない培養液0.5mlを用い同時
に行つた。
アンスロン硫酸法による呈色反応
脱イオン水に溶解し目的濃度にした標品1mlに
2mlのアンスロン試薬(0.20grのアンスロンを
100mlの濃硫酸に溶解したもの)を注加し、混合
30分後、標品1mlに代えて脱イオン水1mlに2ml
のアンスロン試薬を注加した液を対照として
620nmで吸収を測定する。定量値はグルコースを
用いて同様に測定して得た検量式より求める。
次に本発明の実施例を示す。
実施例 1
ストレプトコツカス・ピオゲネス
(Streptococcus pyogenes)ATCC 21060を
BHI培地100mlに接種して37℃、8時間静置培養
をおこなつて得た種培養液を第1表に示す培地
A1に接種し、種培養と同一条件で嫌気的に前
培養を行つた。
第1表 培地A
マルトース 0.25%
肉エキス 1.0%
ポリペプトン 1.0%
酵母エキス 0.25%
酸性第一燐酸カリウム 0.1%
硫酸マグネシウム 0.05%
PH=6.8
10ジヤーフアーメンターに培地A8を投入
して120℃、10分間加熱殺菌後、37℃まで冷却し
て、前培養液1を接種し、37℃、15.5時間、PH
6.8、300回転/分で撹拌しながら窒素置換し、嫌
気的に培養する。次いでペニシリンG1000単位/
ml培養液になるように添加して、培養を更に5時
間継続した。得られた培養液を遠心分離にかけて
菌体を除去した。
培養濾液には硫酸アンモニウムを添加し、50〜
90%飽和度で沈澱する画分を分取した。この硫安
塩析標品を1×10-2M.PH7.0の燐酸緩衝液
(KH2PO4―Na2HPO4)300mlに溶解し、この水
溶液をDEAEセルロースカラム(5×70cm)に吸
着させた後、0.3M 塩化ナトリウムを含む上記
燐酸緩衝液を用いて、段階的に溶出させ、アンス
ロン硫酸法による呈色反応陽性でかつ培養細胞
L 1210の生育を阻害する活性画分を分取した。
この活性画分を、DEAEセフアデツクスA―25
カラム(2.6×70cm)に吸着させ、次いで上記燐
酸緩衝液中の塩化ナトリウム濃度を直線的に上昇
させて溶出を行い、アンスロン硫酸法による呈色
反応陽性でかつ培養細胞 L 1210の生育を阻害
する活性画分を分取した。
この溶出曲線は第3図に示される。第3図にお
いて点線部分は緩衝液の非吸着部分で、実線部分
は塩化ナトリウム濃度を直線的に上昇させて溶出
する部分である。Aは培養細胞 L 1210生育阻
害活性画分であり、Bは高分子透過性大腸菌変異
株MP―2(特開昭60−30689)生育阻害活性画分
である。
Aの活性画分の溶出液は、硫酸アンモニウムを
90%飽和度まで添加し沈澱画分として、上記燐酸
緩衝液に溶解し、透析膜を用いて脱塩後凍結乾燥
して、SPF―10 6.5grを得た。
この抗腫瘍性成分SPF―10を標品とした抗腫瘍
活性試験は実験例1および2に示される。
実施例 2
ストレプトコツカス・ピオゲネスATCC 21060
を第1表に示した培地Aを用いて実施例1と同様
に培養した。この場合、ペニシリンGは300単
位/ml培養液となるように添加し、更に培養を10
時間継続した。この培養濾液を実施例1と同様に
精製して抗腫瘍性成分SPF―10 4.1grを得た。
実施例 3
ストレプトコツカス・ビオゲネスATCC 21060
を第1表に示した培地Aを用いて実施例1と同様
に培養した。この場合ペニシリンGは3000単位/
ml培養液となるように添加し、更に培養を3時間
継続した。この培養濾液を実施例1と同様に精製
して抗腫瘍性成分SPF―10 6.8grを得た。
実施例 4
ストレプトコツカス・ピオゲネスATCC 21060
を第2表に示す培地Bを用いて実施例1と同様に
培養した。この場合ペニシリンGは1000単位/ml
培養液となるように添加し、更に培養を5時間継
続した。この培養濾液を実施例1と同様に精製し
て抗腫瘍性成分SPF―10 5.6grを得た。
第2表 培地B
マルトース 0.1%
肉エキス 0.5%
ポリペプトン 1.0%
酵母エキス 0.25%
塩化ナトリウム 0.1%
PH=7.2
実施例 5
ストレプトコツカス・ピオゲネスATCC 21060
を第3表に示す培地Cを用いて、実施例1と同様
に35℃で培養した。この場合、ペニシリンGは
1000単位/ml培養液となるように添加し、更に培
養を5時間継続した。この培養濾液を実施例1と
同様に精製して抗腫瘍性成分SPF―10 5.5grを得
た。
第3表 培地C
マルトース 0.1%
肉エキス 0.5%
ポリペプトン 0.5%
カザミノ酸 0.3%
酵母エキス 0.5%
酸性第一燐酸カリウム 0.1%
硫酸マグネシウム 0.05%
PH=6.5
実施例 6
ストレプトコツカス・ピオゲネスATCC 21060
を第4表に示す培地Dを用いて実施例1と同様に
培養した。この場合ペニシリンGは1000単位/ml
培養液となるように添加し、更に培養を5時間継
続した。この培養濾液を実施例1と同様に精製し
て抗腫瘍性成分SPF―10 5.9grを得た。
第4表 培地D
マルトース 0.25%
カザミノ酸 0.3%
酵母エキス 1.0%
酸性第一燐酸カリウム 0.1%
硫酸マグネシウム 0.05%
PH=6.9
実施例 7
ストレプトコツカス・エスピーATCC 21597を
第1表に示した培地Aを用いて実施例1と同様に
培養した。この場合ペニシリンGは1000単位/ml
培養液となるように添加し、更に培養を5時間継
続した。この培養濾液を実施例1と同様に精製し
て抗腫瘍性成分SPF―10 3.2grを得た。
実施例 8
ストレプトコツカス・ピオゲネスATCC 21546
を第1表に示す培地Aを用いて実施例1と同様に
培養した。この場合、ペニシリンGは1000単位/
ml培養液となるように添加し、更に培養を5時間
継続した。この培養濾液を実施例1と同様に精製
して抗腫瘍性成分SPF―10 3.8grを得た。
実施例 9
ストレプトコツカス・ピオゲネスATCC 21547
を第1表に示した培地Aを用いて実施例1と同様
に培養した。この場合、ペニシリンGは1000単
位/ml培養液となるように添加し、更に培養を5
時間継続した。この培養濾液を実施例1と同様様
に精製して抗腫瘍性成分SPF―10 4.6grを得た。
実施例 10
ストレプトコツカス・ピオゲネスATCC 21548
を第1表に示した培地Aを用いて実施例1と同様
に培養した。この場合、ペニシリンGは1000単
位/ml培養液となるように添加し、更に培養を5
時間継続した。この培養濾液を実施例1と同様に
精製して抗腫瘍性成分SPF―10 2.3grを得た。
実施例 11
ストレプトコツカス ピオゲネスATCC 21060
を第1表に示した培地Aを用いて実施例1と同様
に培養した。この場合、セフアロスポリンCは
600μg/ml培養液となるように添加し、更に培
養を5時間継続した。この培養濾液を実施例1と
同様に精製して抗腫瘍性成分SPF―10 2.4grを得
た。
実験例 1
実施例1で得られた抗腫瘍性成分SPF―10のイ
ンビトロ(in vitro)における抗腫瘍活性試験
は、本文中に記載した抗腫瘍活性の測定方法によ
り行い、その結果を表―5に示す。
表―5 SPF―10の抗腫瘍活性の結果
SPF―10(mg/ml) IR%
2.0 100
1.0 98
0.5 89
実験例 2
実施例1で得られた抗腫瘍性成分SPF―10のイ
ンビボ(in vivo)における抗腫瘍活性試験は
CRJ―CD―1(ICR系、雌性7週齢)マウスを使
用して実施した。
腫瘍細胞としてはサルコーマ―180腹水癌細胞
を用い、これを生理食塩水に浮遊させ、マウスの
腹腔内に5×105cells/マウス接種した。
癌細胞接種24時間後から1日1回5日間連続し
てSPF―10を腹腔内に投与してその生存数を観察
し、その結果を表―6に示す。
【表】DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel antitumor component SPF-10 and a method for producing the same. Conventionally, hemolytic streptococcus (hereinafter referred to as streptococcus)
Attenuated viable bacterial cells have been prepared and are already being used as anticancer drugs. In addition, after crushing the cells of hemolytic streptococcus, the active ingredients are extracted with water or a saline solution, an organic solvent is added, and the antitumor ingredients are precipitated and recovered.
1647), a method of lysing hemolytic streptococci with the lytic enzyme lysozyme, cellulase or proteolytic enzyme, and fractionating the active fraction as a water-soluble fraction (British patent
1163865), and a method in which water-insoluble substances are collected after crushing the cells of hemolytic streptococcus and treated with a nuclease and a protease (Japanese Patent Application Laid-Open No. 7014-1982). As described above, it is widely known that Streptococcus bacteria themselves or their bacterial cell components have antitumor activity. It was nothing more than a constituent substance. If you try to isolate the active ingredient from the bacterial body or inside the bacterial body,
It was necessary to fractionate the entire bacterial body by lysing it or mechanically crushing it. Such treatments complicate purification and isolation of active ingredients is extremely difficult. In cases where the active ingredient was actually separated and measured, the molecular weight
200,000 proteins (Special Publication No. 43841, No. 43841, No. 43841, No. 43841)
44,617) and a glycoprotein with a molecular weight of 150,000 (Unexamined Japanese Patent Publication No. 1983
−22026) is known. The present inventors previously conducted research to find a method for eluting antitumor components into the culture solution of hemolytic streptococcus, and found that by adding penicillin or related substances during the culture, the antitumor components could be eluted. They discovered that SPF-1 is eluted into the culture solution (Japanese Patent Application Laid-Open No. 60-92218), and were able to isolate the physiologically active substance SPF-1 from the culture solution. (Japanese Patent Application Laid-Open No. 60-30689) The present inventors further conducted intensive research with the aim of isolating a more effective component from the culture filtrate of hemolytic streptococcus.
We have isolated the antitumor component SPF-10, which inhibits the growth of L1210 (hereinafter referred to as cultured cell L1210) and is characterized by being a positive color reaction fraction by the Anthrone sulfuric acid method. The antitumor component SPF-10 of the present invention is determined by elemental analysis,
Although it is thought to be a peptide-like substance containing sugar based on the color reaction, etc., the ultraviolet absorption spectrum indicates that it is a new substance that is different from known antitumor substances. The present invention relates to the production of antitumor component SPF-10, which is characterized by culturing antitumor component SPF-10-producing bacteria belonging to the genus Streptococcus and collecting antitumor component SPF-10 from the culture. It encompasses the law. In the present invention, bacteria that produce the antitumor component SPF-10 belonging to the genus Streptococcus can be widely used. Next, the bacteria producing the antitumor component SPF-10 will be described. Streptococcus pyogenes ATCC 21060 Streptococcus sp. ATCC 21597 Streptococcus pyogenes ATCC 21546 Streptococcus pyogenes ATCC 21547 Streptococcus pyogenes ATCC 21548 The culture medium is meat extract Medium, Yeast Extract Medium, Brain Heart Infusion Medium (BHI
A natural medium such as Streptococcus spp. is often used, but any medium can be used as long as it is suitable for the growth of Streptococcus bacteria. The culture is performed at a pH of 5.0 to 8.0, preferably 6.1 to 7.2, and a culture temperature of 30 to 40°C, preferably 35 to 37°C.
℃, and static culture or stirring culture can be performed anaerobically. In the present invention, adding penicillin or its related substances at an appropriate time during culture plays an important role in collecting the antitumor component SPF-10. The addition time of penicillin or related substances is
After culturing at 35-37℃ and reaching the logarithmic growth phase,
A period between ˜20 hours, especially 5 to 10 hours is preferred. After that, by continuing the culture for 1 to 20 hours, preferably 3 to 15 hours, the antitumor component SPF-10 is added during the culture.
can be accumulated in large amounts. Penicillin or its related substances may be any known related substances that have similar effects to penicillin, but penicillin G is commonly used. The amount added is penicillin G.
A concentration of 100 to 7000 units/ml, preferably 300 to 5000 units/ml of culture solution is sufficient. The culture solution obtained by culturing Streptococcus bacteria with the addition of penicillin or related substances is centrifuged to remove the bacterial cells, and ammonium sulfate is added to the filtrate. Separate the amount.
The obtained ammonium sulfate precipitate containing the antitumor component SPF-10 can also be stored in a frozen state. To extract the antitumor component SPF-10 from this ammonium sulfate salt precipitate, the salt precipitate is dissolved in a buffer solution, this aqueous solution is adsorbed on a DEAE cellulose column, and it is eluted stepwise using a phosphate buffer solution. , cultured cells L
Collect the active fraction that inhibits the growth of 1210, adsorb this active fraction onto a DEAE Sephadex A-25 column, and elute it by linearly increasing the sodium chloride concentration in the phosphate buffer. It can be obtained by separating the non-buffer-adsorbed portion and the low sodium chloride concentration portion, desalting them, and freeze-drying them. Next, the antitumor component SPF obtained in Example 1
The 10 freeze-dried specimens exhibit the following physical and chemical properties. 1 Elemental analysis C 45.6-46.1% H 6.5-6.6% N 14.8-15.4% O 29.8-32.2% Ash 0.9-2.1% 2 Decomposition point This substance turns brown at 165°C and turns black at 240°C and decomposes. 3 Specific rotation [α] 20 D = -65°.0 to -85.0° (C = 1.00) 4 Ultraviolet absorption spectrum The ultraviolet absorption spectrum of a 0.1% aqueous solution of this substance is shown in FIG. Absorption is observed from 250nm to 270nm. 5 Infrared absorption spectrum Shown in Figure 2. Around 3270cm -1 , 2900cm -1 , 1670cm -1 , 1535cm
-1 , 1450cm -1 , 1400cm -1 , 1330cm -1 , 1260cm -1 ,
Absorption is observed at 1160cm -1 , 1090cm -1 and 1030cm -1 . 6. Distinction between basic, acidic, and neutral The pH of a 1.0% aqueous solution of this substance is 6.5. 7 Color of substance Pale yellow 8 Color reaction Lowry reaction + Bieurett reaction + Ninhydrin reaction + Anthrone sulfuric acid reaction + Mauritsch reaction + Cysteine sulfuric acid reaction + Orsine hydrochloric acid reaction - 9 Molecular weight Molecular weight approximately 1000 ~ as measured by gel filtration method
500000. 10 Solubility in solvents Soluble in water, methanol, ethanol,
n-propanol, acetone, ethyl ether,
It is sparingly soluble or insoluble in solvents such as n-hexane, chloroform, and ethyl acetate. Next, a method for measuring antitumor activity against cultured cells L 1210 in vitro and a color reaction method using the Anthrone sulfuric acid method will be described. Method for measuring antitumor activity Antitumor activity was measured by measuring the growth inhibition rate (IR%) of cultured cells L1210. L 1210 cells were suspended in RPMI 1640 medium (containing 5 mg/kanamycin) supplemented with 10% FBS. 0.5 ml of this culture solution was poured into a Falcon 2058 tube so that the number of cells was 1×10 5 cells/tube. Next, 0.5 ml of a predetermined amount of the standard product (anti-tumor component SPF-10) dissolved in the culture solution to the desired concentration was added to this culture solution, and cultured at 37°C in the presence of 5% CO2 . did. 48 hours after adding the standard sample, staining with trypan blue was performed using the following formula.
IR (%) was calculated. IR (%) = (A) - Number of viable cells in each experimental group/Number of viable cells in control group x 100 Here, (A) indicates the number of viable cells in the control group. A control was performed at the same time using 0.5 ml of culture solution that did not contain the standard. Color reaction using the Anthrone sulfuric acid method Add 2 ml of Anthrone reagent (0.20 gr of Anthrone to 1 ml of the sample dissolved in deionized water to the desired concentration).
(dissolved in 100ml of concentrated sulfuric acid) and mix.
After 30 minutes, replace 1 ml of standard with 2 ml in 1 ml of deionized water.
The solution containing Anthrone reagent was used as a control.
Measure absorption at 620nm. The quantitative value is obtained from a calibration formula obtained by measuring in the same manner using glucose. Next, examples of the present invention will be shown. Example 1 Streptococcus pyogenes ATCC 21060
The seed culture solution obtained by inoculating 100ml of BHI medium and statically culturing at 37℃ for 8 hours is used as the medium shown in Table 1.
A1 was inoculated and precultured anaerobically under the same conditions as the seed culture. Table 1 Medium A Maltose 0.25% Meat extract 1.0% Polypeptone 1.0% Yeast extract 0.25% Acidic monobasic potassium phosphate 0.1% Magnesium sulfate 0.05% PH=6.8 10 Pour medium A8 into a jar fermenter and heat at 120℃ for 10 minutes After heat sterilization, cool to 37℃, inoculate with preculture solution 1, and incubate at 37℃ for 15.5 hours at PH.
6.8, replace with nitrogen while stirring at 300 rpm and culture anaerobically. Then penicillin G1000 units/
ml culture solution, and culture was continued for an additional 5 hours. The resulting culture solution was centrifuged to remove bacterial cells. Add ammonium sulfate to the culture filtrate and
A fraction precipitated at 90% saturation was collected. This ammonium sulfate salting-out sample was dissolved in 300 ml of phosphate buffer (KH 2 PO 4 -Na 2 HPO 4 ) of 1 × 10 -2 M.PH7.0, and this aqueous solution was adsorbed on a DEAE cellulose column (5 × 70 cm). After that, the cells were eluted stepwise using the above phosphate buffer containing 0.3M sodium chloride, and if the color reaction by the Anthrone sulfuric acid method was positive and the cultured cells were
An active fraction that inhibits the growth of L 1210 was collected. This active fraction was added to DEAE Sephadex A-25.
Adsorb onto a column (2.6 x 70 cm), then elute by linearly increasing the sodium chloride concentration in the phosphate buffer, and the color reaction by the Anthrone sulfuric acid method is positive and the growth of cultured cells L 1210 is inhibited. The active fraction was collected. This elution curve is shown in FIG. In FIG. 3, the dotted line part is the part where the buffer solution is not adsorbed, and the solid line part is the part eluted by linearly increasing the sodium chloride concentration. A is a fraction with growth inhibition activity of cultured cell L 1210, and B is a fraction with growth inhibition activity of polymer-permeable E. coli mutant strain MP-2 (JP-A-60-30689). The eluate of the active fraction of A was treated with ammonium sulfate.
The precipitated fraction was dissolved in the above phosphate buffer, desalted using a dialysis membrane, and then lyophilized to obtain 6.5 gr of SPF-10. An antitumor activity test using this antitumor component SPF-10 as a standard is shown in Experimental Examples 1 and 2. Example 2 Streptococcus pyogenes ATCC 21060
were cultured in the same manner as in Example 1 using medium A shown in Table 1. In this case, penicillin G was added at 300 units/ml culture solution, and the culture was further increased by 10
Lasted for an hour. This culture filtrate was purified in the same manner as in Example 1 to obtain 4.1 gr of antitumor component SPF-10. Example 3 Streptococcus biogenes ATCC 21060
were cultured in the same manner as in Example 1 using medium A shown in Table 1. In this case, penicillin G is 3000 units/
ml culture solution, and culture was continued for an additional 3 hours. This culture filtrate was purified in the same manner as in Example 1 to obtain 6.8 gr of antitumor component SPF-10. Example 4 Streptococcus pyogenes ATCC 21060
were cultured in the same manner as in Example 1 using medium B shown in Table 2. In this case, penicillin G is 1000 units/ml.
The mixture was added to form a culture solution, and the culture was continued for an additional 5 hours. This culture filtrate was purified in the same manner as in Example 1 to obtain 5.6 gr of antitumor component SPF-10. Table 2 Medium B Maltose 0.1% Meat extract 0.5% Polypeptone 1.0% Yeast extract 0.25% Sodium chloride 0.1% PH=7.2 Example 5 Streptococcus pyogenes ATCC 21060
were cultured at 35° C. in the same manner as in Example 1 using medium C shown in Table 3. In this case, penicillin G
The mixture was added at a concentration of 1000 units/ml culture solution, and the culture was continued for an additional 5 hours. This culture filtrate was purified in the same manner as in Example 1 to obtain 5.5 gr of antitumor component SPF-10. Table 3 Medium C Maltose 0.1% Meat extract 0.5% Polypeptone 0.5% Casamino acids 0.3% Yeast extract 0.5% Acidic potassium monophosphate 0.1% Magnesium sulfate 0.05% PH=6.5 Example 6 Streptococcus pyogenes ATCC 21060
were cultured in the same manner as in Example 1 using medium D shown in Table 4. In this case, penicillin G is 1000 units/ml.
The mixture was added to form a culture solution, and the culture was continued for an additional 5 hours. This culture filtrate was purified in the same manner as in Example 1 to obtain 5.9 gr of antitumor component SPF-10. Table 4 Medium D Maltose 0.25% Casamino acids 0.3% Yeast extract 1.0% Acidic monobasic potassium phosphate 0.1% Magnesium sulfate 0.05% PH=6.9 Example 7 Streptococcus sp. ATCC 21597 was grown in medium A shown in Table 1. The cells were cultured in the same manner as in Example 1. In this case, penicillin G is 1000 units/ml.
The mixture was added to form a culture solution, and the culture was continued for an additional 5 hours. This culture filtrate was purified in the same manner as in Example 1 to obtain 3.2 gr of antitumor component SPF-10. Example 8 Streptococcus pyogenes ATCC 21546
were cultured in the same manner as in Example 1 using medium A shown in Table 1. In this case, penicillin G is 1000 units/
ml culture solution, and culture was continued for an additional 5 hours. This culture filtrate was purified in the same manner as in Example 1 to obtain 3.8 gr of antitumor component SPF-10. Example 9 Streptococcus pyogenes ATCC 21547
were cultured in the same manner as in Example 1 using medium A shown in Table 1. In this case, penicillin G is added at 1000 units/ml culture solution, and the culture is further
Lasted for an hour. This culture filtrate was purified in the same manner as in Example 1 to obtain 4.6 gr of antitumor component SPF-10. Example 10 Streptococcus pyogenes ATCC 21548
were cultured in the same manner as in Example 1 using medium A shown in Table 1. In this case, penicillin G is added at 1000 units/ml culture solution, and the culture is further
Lasted for an hour. This culture filtrate was purified in the same manner as in Example 1 to obtain 2.3 gr of antitumor component SPF-10. Example 11 Streptococcus pyogenes ATCC 21060
were cultured in the same manner as in Example 1 using medium A shown in Table 1. In this case, cephalosporin C is
The mixture was added at a concentration of 600 μg/ml culture solution, and the culture was continued for an additional 5 hours. This culture filtrate was purified in the same manner as in Example 1 to obtain 2.4 gr of antitumor component SPF-10. Experimental Example 1 The in vitro antitumor activity test of the antitumor component SPF-10 obtained in Example 1 was conducted using the method for measuring antitumor activity described in the text, and the results are shown in Table 5. Shown below. Table 5 Results of antitumor activity of SPF-10 SPF-10 (mg/ml) IR% 2.0 100 1.0 98 0.5 89 Experimental example 2 In vivo ) antitumor activity test in
The experiment was carried out using CRJ-CD-1 (ICR strain, female, 7 weeks old) mice. Sarcoma-180 ascites cancer cells were used as tumor cells, suspended in physiological saline, and inoculated intraperitoneally into mice at 5×10 5 cells/mouse. Starting 24 hours after cancer cell inoculation, SPF-10 was administered intraperitoneally once a day for 5 consecutive days, and the number of survivors was observed. The results are shown in Table 6. 【table】
第1図は抗腫瘍性成分SPF―10の紫外線吸収ス
ペクトルを示し、第2図は同じく赤外線吸収スペ
クトルを示す。第3図は実施例1における活性画
分のDEAEセフアデツクスA―25カラムの溶出曲
線を示す図である。
Figure 1 shows the ultraviolet absorption spectrum of the antitumor component SPF-10, and Figure 2 also shows the infrared absorption spectrum. FIG. 3 is a diagram showing the elution curve of the active fraction in Example 1 on a DEAE Sephadex A-25 column.
Claims (1)
SPF―10。 1 元素分析 C 45.6〜46.1% H 6.5〜6.6% N 14.8〜15.4% O 29.8〜32.2% Ash 0.9〜2.1% 2 分解点 本物質は165℃で褐変し、240℃になると黒色と
なり分解する。 3 比旋光度 〔α〕20 D=−65.0゜〜−85.0゜(C=1.00) 4 紫外線吸収スペクトル 本物質の0.1%の水溶液の紫外線吸収スペクト
ルは、250nmから270nmにかけて吸収が認められ
る。 5 赤外線吸収スペクトル 3270cm-1付近、2900cm-1、1670cm-1、1535cm
-1、1450cm-1、1400cm-1、1330cm-1、1260cm-1、
1160cm-1、1090cm-1、1030cm-1 に吸収が認められる。 6 塩基性、酸性、中性の区別 本物質の1.0%の水溶液のPHは6.5である。 7 物質の色 淡褐色 8 呈色反応 ローリー反応 + ビユーレツト反応 + ニンヒドリン反応 + アンスロン硫酸反応 + モーリツシユ反応 + システイン硫酸反応 + オルシン塩酸反応 − 9 分子量 ゲル濾過法による測定では、分子量約1000〜
500000である。 10 溶剤に対する溶解性 水に可溶であるが、メタノール、エタノール、
n―プロパノール、アセトン、エチルエーテル、
n―ヘキサン、クロロホルム、酢酸エチル等の溶
剤には難溶又は不溶である。 2 ストレプトコツカス属に属する抗腫瘍性成分
SPF―10生産菌を培養し、培養物から抗腫瘍性成
分SPF―10を採取することを特徴とする抗腫瘍性
物質SPF―10の製法。 3 ストレプトコツカス属に属する抗腫瘍性成分
SPF―10生産菌を培養するに際し、培養中の適当
な時期にペニシリン又はその関連物質を添加して
培養することを特徴とする特許請求の範囲第2項
に記載の抗腫瘍性成分SPF―10の製法。[Claims] 1. Antitumor component having the following physicochemical properties:
SPF-10. 1 Elemental analysis C 45.6-46.1% H 6.5-6.6% N 14.8-15.4% O 29.8-32.2% Ash 0.9-2.1% 2 Decomposition point This substance turns brown at 165°C and turns black at 240°C and decomposes. 3 Specific rotation [α] 20 D = -65.0° to -85.0° (C = 1.00) 4 Ultraviolet absorption spectrum In the ultraviolet absorption spectrum of a 0.1% aqueous solution of this substance, absorption is observed from 250 nm to 270 nm. 5 Infrared absorption spectrum around 3270cm -1 , 2900cm -1 , 1670cm -1 , 1535cm
-1 , 1450cm -1 , 1400cm -1 , 1330cm -1 , 1260cm -1 ,
Absorption is observed at 1160cm -1 , 1090cm -1 and 1030cm -1 . 6. Distinction between basic, acidic, and neutral The pH of a 1.0% aqueous solution of this substance is 6.5. 7 Color of the substance Light brown 8 Color reaction Lowry reaction + Bieurett reaction + Ninhydrin reaction + Anthrone sulfuric acid reaction + Moritzhu reaction + Cysteine sulfuric acid reaction + Orsine hydrochloric acid reaction - 9 Molecular weight When measured by gel filtration method, the molecular weight is about 1000 ~
500000. 10 Solubility in solvents Soluble in water, methanol, ethanol,
n-propanol, acetone, ethyl ether,
It is sparingly soluble or insoluble in solvents such as n-hexane, chloroform, and ethyl acetate. 2 Antitumor component belonging to the genus Streptococcus
A method for producing an antitumor substance SPF-10, which is characterized by culturing SPF-10 producing bacteria and collecting the antitumor substance SPF-10 from the culture. 3 Antitumor component belonging to the genus Streptococcus
Antitumor component SPF-10 according to claim 2, characterized in that when culturing the SPF-10 producing bacteria, penicillin or a related substance is added at an appropriate time during the culture. manufacturing method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60152326A JPS6216426A (en) | 1985-07-12 | 1985-07-12 | Antitumor component spf-10 and production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60152326A JPS6216426A (en) | 1985-07-12 | 1985-07-12 | Antitumor component spf-10 and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6216426A JPS6216426A (en) | 1987-01-24 |
JPH0156074B2 true JPH0156074B2 (en) | 1989-11-28 |
Family
ID=15538081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60152326A Granted JPS6216426A (en) | 1985-07-12 | 1985-07-12 | Antitumor component spf-10 and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6216426A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63212980A (en) * | 1988-02-12 | 1988-09-05 | 松下電器産業株式会社 | Transmission type liquid crystal matrix display device |
-
1985
- 1985-07-12 JP JP60152326A patent/JPS6216426A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS6216426A (en) | 1987-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4533548A (en) | Acidic polysaccharide CH-1 isolated from Chlorella pyrenoidosa and the use thereof | |
HU188684B (en) | Process for producing a2, and simultaneously produced a1 and a3 components of antibioticum a/16686 | |
US4209507A (en) | Novel anti-tumor substance and preparation thereof | |
JPH0670078B2 (en) | Polypeptide antibiotics | |
EP0668358B1 (en) | Antibiotic WAP-8294A, method for preparing the same and antibacterial composition | |
US4837149A (en) | Novel saframycin A derivatives and process for producing the same | |
JPH0156074B2 (en) | ||
JPS60246396A (en) | Enzyme-inhibiting substance dihydrodesoxy griseolic acid and its salt | |
JPH0156076B2 (en) | ||
JPH0571232B2 (en) | ||
JPH0156075B2 (en) | ||
KR860001213B1 (en) | Novel process for preparing substance having carcinostatic and immunostimulating activity | |
JPH0571230B2 (en) | ||
JPH0571231B2 (en) | ||
JP2546239B2 (en) | Novel substance ovalicin | |
JPH0155276B2 (en) | ||
JPH0156073B2 (en) | ||
JPH0156078B2 (en) | ||
JPS63101400A (en) | Antitumor ingredient spf-pco-20 | |
JP2856379B2 (en) | Protein phosphatase inhibitor and antitumor agent | |
JPH07506332A (en) | Phosphate esters of heterocyclic compounds as medicines | |
JPS63101392A (en) | Antitumor ingredient spf-pco-30 | |
JPH0156077B2 (en) | ||
JPS6326994B2 (en) | ||
JPH0155274B2 (en) |